Subcarinal lymph node in upper lobe non-small cell lung cancer patients

Is selective lymph node dissection valid?

Keiju Aokage, Junji Yoshida, Genichiro Ishii, Tomoyuki Hishida, Mitsuyo Nishimura, Kanji Nagai

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Little is known about selective lymph node dissection in non-small cell lung cancer (NSCLC) patients. We sought to gain insight into subcarinal node involvement for its frequency and impact on outcome to evaluate whether it is valid to omit subcarinal lymph node dissection in upper lobe NSCLC patients. We reviewed node metastases distribution according to node region, tumor location, and histology among 1099 patients with upper lobe NSCLC. We paid special attention to subcarinal metastases patients without superior mediastinal node metastases, because their pathological stages would have been underdiagnosed if subcarinal node dissection had been omitted. We also assessed the outcome and the pattern of failure among subcarinal metastases patients. To identify subcarinal node involvement predictors, we analyzed 7 clinical factors. Subcarinal node metastases were found in 20 patients and were least frequent among squamous cell carcinoma patients (0.5%). Two of them were free from superior mediastinal metastases but died of the disease at 1 month and due to an unknown cause at 18 months, respectively. Seventeen of the 20 patients developed multi-site recurrence within 37 months. The 5-year survival rate of the 20 patients with subcarinal metastases was 9.0%, which was significantly lower than 32.0% of patients with only superior mediastinal metastases. Clinical diagnosis of node metastases was significantly predictive of subcarinal metastases. Subcarinal node metastases from upper lobe NSCLC were rare and predicted an extremely poor outcome. It appears valid to omit subcarinal node dissection in upper lobe NSCLC patients, especially in clinical N0 squamous cell carcinoma patients.

Original languageEnglish
Pages (from-to)163-167
Number of pages5
JournalLung Cancer
Volume70
Issue number2
DOIs
Publication statusPublished - 2010 Nov
Externally publishedYes

Fingerprint

Lymph Node Excision
Non-Small Cell Lung Carcinoma
Lymph Nodes
Neoplasm Metastasis
Dissection
Squamous Cell Carcinoma
Histology
Survival Rate
Recurrence

Keywords

  • Lymphadenectomy
  • Minimally invasive surgery
  • Non-small cell lung cancer
  • Selective lymph node dissection
  • Subcarina
  • Surgery

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Subcarinal lymph node in upper lobe non-small cell lung cancer patients : Is selective lymph node dissection valid? / Aokage, Keiju; Yoshida, Junji; Ishii, Genichiro; Hishida, Tomoyuki; Nishimura, Mitsuyo; Nagai, Kanji.

In: Lung Cancer, Vol. 70, No. 2, 11.2010, p. 163-167.

Research output: Contribution to journalArticle

Aokage, Keiju ; Yoshida, Junji ; Ishii, Genichiro ; Hishida, Tomoyuki ; Nishimura, Mitsuyo ; Nagai, Kanji. / Subcarinal lymph node in upper lobe non-small cell lung cancer patients : Is selective lymph node dissection valid?. In: Lung Cancer. 2010 ; Vol. 70, No. 2. pp. 163-167.
@article{26e15a2347924ac79959eac1200e1df2,
title = "Subcarinal lymph node in upper lobe non-small cell lung cancer patients: Is selective lymph node dissection valid?",
abstract = "Little is known about selective lymph node dissection in non-small cell lung cancer (NSCLC) patients. We sought to gain insight into subcarinal node involvement for its frequency and impact on outcome to evaluate whether it is valid to omit subcarinal lymph node dissection in upper lobe NSCLC patients. We reviewed node metastases distribution according to node region, tumor location, and histology among 1099 patients with upper lobe NSCLC. We paid special attention to subcarinal metastases patients without superior mediastinal node metastases, because their pathological stages would have been underdiagnosed if subcarinal node dissection had been omitted. We also assessed the outcome and the pattern of failure among subcarinal metastases patients. To identify subcarinal node involvement predictors, we analyzed 7 clinical factors. Subcarinal node metastases were found in 20 patients and were least frequent among squamous cell carcinoma patients (0.5{\%}). Two of them were free from superior mediastinal metastases but died of the disease at 1 month and due to an unknown cause at 18 months, respectively. Seventeen of the 20 patients developed multi-site recurrence within 37 months. The 5-year survival rate of the 20 patients with subcarinal metastases was 9.0{\%}, which was significantly lower than 32.0{\%} of patients with only superior mediastinal metastases. Clinical diagnosis of node metastases was significantly predictive of subcarinal metastases. Subcarinal node metastases from upper lobe NSCLC were rare and predicted an extremely poor outcome. It appears valid to omit subcarinal node dissection in upper lobe NSCLC patients, especially in clinical N0 squamous cell carcinoma patients.",
keywords = "Lymphadenectomy, Minimally invasive surgery, Non-small cell lung cancer, Selective lymph node dissection, Subcarina, Surgery",
author = "Keiju Aokage and Junji Yoshida and Genichiro Ishii and Tomoyuki Hishida and Mitsuyo Nishimura and Kanji Nagai",
year = "2010",
month = "11",
doi = "10.1016/j.lungcan.2010.02.009",
language = "English",
volume = "70",
pages = "163--167",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Subcarinal lymph node in upper lobe non-small cell lung cancer patients

T2 - Is selective lymph node dissection valid?

AU - Aokage, Keiju

AU - Yoshida, Junji

AU - Ishii, Genichiro

AU - Hishida, Tomoyuki

AU - Nishimura, Mitsuyo

AU - Nagai, Kanji

PY - 2010/11

Y1 - 2010/11

N2 - Little is known about selective lymph node dissection in non-small cell lung cancer (NSCLC) patients. We sought to gain insight into subcarinal node involvement for its frequency and impact on outcome to evaluate whether it is valid to omit subcarinal lymph node dissection in upper lobe NSCLC patients. We reviewed node metastases distribution according to node region, tumor location, and histology among 1099 patients with upper lobe NSCLC. We paid special attention to subcarinal metastases patients without superior mediastinal node metastases, because their pathological stages would have been underdiagnosed if subcarinal node dissection had been omitted. We also assessed the outcome and the pattern of failure among subcarinal metastases patients. To identify subcarinal node involvement predictors, we analyzed 7 clinical factors. Subcarinal node metastases were found in 20 patients and were least frequent among squamous cell carcinoma patients (0.5%). Two of them were free from superior mediastinal metastases but died of the disease at 1 month and due to an unknown cause at 18 months, respectively. Seventeen of the 20 patients developed multi-site recurrence within 37 months. The 5-year survival rate of the 20 patients with subcarinal metastases was 9.0%, which was significantly lower than 32.0% of patients with only superior mediastinal metastases. Clinical diagnosis of node metastases was significantly predictive of subcarinal metastases. Subcarinal node metastases from upper lobe NSCLC were rare and predicted an extremely poor outcome. It appears valid to omit subcarinal node dissection in upper lobe NSCLC patients, especially in clinical N0 squamous cell carcinoma patients.

AB - Little is known about selective lymph node dissection in non-small cell lung cancer (NSCLC) patients. We sought to gain insight into subcarinal node involvement for its frequency and impact on outcome to evaluate whether it is valid to omit subcarinal lymph node dissection in upper lobe NSCLC patients. We reviewed node metastases distribution according to node region, tumor location, and histology among 1099 patients with upper lobe NSCLC. We paid special attention to subcarinal metastases patients without superior mediastinal node metastases, because their pathological stages would have been underdiagnosed if subcarinal node dissection had been omitted. We also assessed the outcome and the pattern of failure among subcarinal metastases patients. To identify subcarinal node involvement predictors, we analyzed 7 clinical factors. Subcarinal node metastases were found in 20 patients and were least frequent among squamous cell carcinoma patients (0.5%). Two of them were free from superior mediastinal metastases but died of the disease at 1 month and due to an unknown cause at 18 months, respectively. Seventeen of the 20 patients developed multi-site recurrence within 37 months. The 5-year survival rate of the 20 patients with subcarinal metastases was 9.0%, which was significantly lower than 32.0% of patients with only superior mediastinal metastases. Clinical diagnosis of node metastases was significantly predictive of subcarinal metastases. Subcarinal node metastases from upper lobe NSCLC were rare and predicted an extremely poor outcome. It appears valid to omit subcarinal node dissection in upper lobe NSCLC patients, especially in clinical N0 squamous cell carcinoma patients.

KW - Lymphadenectomy

KW - Minimally invasive surgery

KW - Non-small cell lung cancer

KW - Selective lymph node dissection

KW - Subcarina

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=77957018816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957018816&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2010.02.009

DO - 10.1016/j.lungcan.2010.02.009

M3 - Article

VL - 70

SP - 163

EP - 167

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -